Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR443820 phase 2 study in adults with amyotrophic lateral sclerosis
NL-OMON53447Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing SAR443820 with Placebo (2 arms). Primary endpoints: Change from baseline in ALSFRS-R total score and CAFS score. Started Apr 2022; status: active, not recruiting.
02
Drugs
oditrasertib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON53447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53447.